Literature DB >> 30624691

Knowledge of Late Effects Risks and Healthcare Responsibility in Adolescents and Young Adults Treated for Childhood Cancer.

Jennifer L Lee1,2, Ana Gutierrez-Colina3, Rebecca Williamson Lewis1, Karen Wasilewski-Masker1,2, Lillian R Meacham1,2, Ann C Mertens1,2, Jordan Gilleland Marchak1,2.   

Abstract

OBJECTIVE: This study aimed to examine the level and predictors of knowledge of late effects risks from childhood cancer treatment in adolescent and young adult (AYA) survivors.
METHODS: Seventy-three AYAs, aged 14-21, completed measures of knowledge of late effect risks, executive functioning, and responsibility for health self-management. Sixty-seven parents of these AYA survivors (91.7%) also participated.
RESULTS: Survivors demonstrated poor knowledge of their unique risks for treatment-related late effects, with a mean accurate knowledge score of 54.29% (SD = 24.19%). The number of late effects for which survivors were at risk was negatively correlated with risk knowledge (r = -.34, p < .01). Survivors' executive functioning was not related to risk knowledge. In regression analyses, survivor age positively predicted accurate knowledge of late effects risks, and the number of late effects risk was a negative predictor. In separate models, survivor self-report of AYA responsibility for health self-management did not predict knowledge (R2 = .39, F = 10.86, p < .01), but parent proxy-report was a significant positive predictor (R2 = .38, F = 9.62, p < .01). Parental involvement was not a significant predictor in either model.
CONCLUSION: There are significant knowledge gaps among AYA survivors of childhood cancer, which appear to be related to younger AYA age and lower levels of AYA responsibility for health self-management. Additional intervention is critical to increase AYA knowledge of their risk for late effects in order to promote continued engagement in long-term follow-up care and surveillance across the lifespan.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society of Pediatric Psychology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  adolescent; cancer survivor; health self-management; late effects; pediatric oncology; self-management; young adult

Mesh:

Year:  2019        PMID: 30624691     DOI: 10.1093/jpepsy/jsy102

Source DB:  PubMed          Journal:  J Pediatr Psychol        ISSN: 0146-8693


  5 in total

Review 1.  Advances in pediatric psychooncology.

Authors:  Lori Wiener; Katie A Devine; Amanda L Thompson
Journal:  Curr Opin Pediatr       Date:  2020-02       Impact factor: 2.856

2.  Technology-Assisted Psychosocial Interventions for Childhood, Adolescent, and Young Adult Cancer Survivors: A Systematic Review and Meta-Analysis.

Authors:  Anao Zhang; Bradley Zebrack; Chiara Acquati; Michael Roth; Nina Jackson Levin; Kaipeng Wang; Samantha Schwartz
Journal:  J Adolesc Young Adult Oncol       Date:  2021-05-06       Impact factor: 2.223

3.  Development and Validation of Models to Predict Poor Health-Related Quality of Life Among Adult Survivors of Childhood Cancer.

Authors:  Fiona Schulte; Yan Chen; Yutaka Yasui; Maritza E Ruiz; Wendy Leisenring; Todd M Gibson; Paul C Nathan; Kevin C Oeffinger; Melissa M Hudson; Gregory T Armstrong; Leslie L Robison; Kevin R Krull; I-Chan Huang
Journal:  JAMA Netw Open       Date:  2022-08-01

4.  Self-reported late effects and long-term follow-up care among 1889 long-term Norwegian Childhood, Adolescent, and Young Adult Cancer Survivors (the NOR-CAYACS study).

Authors:  A V Mellblom; C E Kiserud; C S Rueegg; E Ruud; J H Loge; S D Fosså; Hanne C Lie
Journal:  Support Care Cancer       Date:  2020-10-03       Impact factor: 3.603

5.  "I have to do things differently now, but I make it work"-young childhood cancer survivors' experiences of self-management in everyday living.

Authors:  Marie H Larsen; Elna H Larsen; Ellen Ruud; Anneli Mellblom; Sunniva Helland; Hanne Cathrine Lie
Journal:  J Cancer Surviv       Date:  2021-06-07       Impact factor: 4.062

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.